* Connetics Inc.., of Palo Alto, Calif., said Amerindo Investment Advisors Inc., of New York, acquired an additional 125,000 shares of the company's stock, bringing its total investment position to 1.345 million shares, or about 10 percent of Connetics' outstanding shares. Amerindo acquired 1.2 million shares in December 1997 as part of a financing.

* Glaxo Wellcome plc, of London, said patients with HIV or AIDS who are no longer maintaining viral suppression with current treatments will soon be eligible to receive Glaxo's investigational drug, Ziagen (abacavir, formerly known as 1592) through an expanded access program. Patients must be more than 13 years old, failing or intolerant to standard therapy, and unable to construct a viable treatment regimen without Ziagen. Program enrollment opens this month.

* Oxford Asymmetry International (OAI), of Abingdon, U.K., and Dow AgroSciences LLC, of Indianapolis, signed an 18-month research agreement involving the discovery, synthesis and screening of new chemical compounds for agricultural applications. Under terms of the agreement, OAI will provide Dow with novel compounds that show potential for biological activity. Dow will pay a minimum of $1.2 million in fees plus milestone payments for each compound that progresses through trials and royalties.

* Photogen Technologies Inc., of Knoxville, Tenn., completed a private placement of 875,000 shares of stock for $8 per share to a number of accredited investors. Proceeds for the company amounted to $7 million. After issuance of the stock, the company will have 36.875 million shares outstanding. Photogen focuses on photodynamic-related health care products, based on its simultaneous two-photon excitation technology.

* Viragen Inc., of Plantation, Fla., began animal toxicology studies for Omniferon, its second generation, human white blood cell derived natural interferon drug. The company said it expects to file later for regulatory approval to begin human clinical trials. Last fall, Viragen said it was considering genital herpes as the primary disease target for Omniferon.

No Comments